{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T14:59:38Z","timestamp":1780930778606,"version":"3.54.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,8]]},"DOI":"10.7759\/cureus.110453","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T14:13:49Z","timestamp":1780928029000},"source":"Crossref","is-referenced-by-count":0,"title":["Pancreatic Neuroendocrine Tumor in Lynch Syndrome: Expanding the Tumor Spectrum of Mismatch Repair Deficiency"],"prefix":"10.7759","author":[{"given":"Sai Sushrutha","family":"Mudupula Vemula","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumith","family":"Sanka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varun","family":"Natarajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merryl T","family":"Varghese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Isaac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s10689-004-7993-0","article-title":"Lynch syndrome genes","volume":"4","author":"Peltom\u00e4ki P","year":"2005","unstructured":"Peltom\u00e4ki P. Lynch syndrome genes. Fam Cancer. 2005, 4:227-32. 10.1007\/s10689-004-7993-0","journal-title":"Fam Cancer"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2017.00243","article-title":"A systematic review on the existing screening pathways for Lynch syndrome identification","volume":"5","author":"Tognetto A","year":"2017","unstructured":"Tognetto A, Michelazzo MB, Calabr\u00f3 GE, et al.. A systematic review on the existing screening pathways for Lynch syndrome identification. Front Public Health. 2017, 5:243. 10.3389\/fpubh.2017.00243","journal-title":"Front Public Health"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3310\/hta21510","article-title":"Molecular testing for Lynch syndrome in people with colorectal cancer: systematic reviews and economic evaluation","volume":"21","author":"Snowsill T","year":"2017","unstructured":"Snowsill T, Coelho H, Huxley N, Jones-Hughes T, Briscoe S, Frayling IM, Hyde C. Molecular testing for Lynch syndrome in people with colorectal cancer: systematic reviews and economic evaluation. Health Technol Assess. 2017, 21:1-238. 10.3310\/hta21510","journal-title":"Health Technol Assess"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2010.12.005","article-title":"The epidemiology of gastroenteropancreatic neuroendocrine tumors","volume":"40","author":"Lawrence B","year":"2011","unstructured":"Lawrence B, Gustafsson BI, Chan A, Svejda B, Kidd M, Modlin IM. The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am. 2011, 40:1-18, vii. 10.1016\/j.ecl.2010.12.005","journal-title":"Endocrinol Metab Clin North Am"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.21037\/jgo.2017.07.02","article-title":"Pancreatic non-functioning neuroendocrine tumor: a new entity genetically related to Lynch syndrome","volume":"8","author":"Serracant Barrera A","year":"2017","unstructured":"Serracant Barrera A, Serra Pla S, Bl\u00e1zquez Ma\u00f1a CM, et al.. Pancreatic non-functioning neuroendocrine tumor: a new entity genetically related to Lynch syndrome. J Gastrointest Oncol. 2017, 8:E73-9. 10.21037\/jgo.2017.07.02","journal-title":"J Gastrointest Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1123901","article-title":"Clinical characteristics of pancreatic and biliary tract cancers in Lynch syndrome: A retrospective analysis from the Finnish National Lynch Syndrome Research Registry","volume":"13","author":"Zalevskaja K","year":"2023","unstructured":"Zalevskaja K, Mecklin JP, Sepp\u00e4l\u00e4 TT. Clinical characteristics of pancreatic and biliary tract cancers in Lynch syndrome: A retrospective analysis from the Finnish National Lynch Syndrome Research Registry. Front Oncol. 2023, 13:1123901. 10.3389\/fonc.2023.1123901","journal-title":"Front Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1587889","article-title":"Neuroendocrine neoplasms as a lynch syndrome manifestation: a case report and comprehensive literature review","volume":"16","author":"Bernal Z\u00e1rate MP","year":"2025","unstructured":"Bernal Z\u00e1rate MP, Mendivelso-Gonzalez DF, Torres WC, Gonz\u00e1lez Clavijo AM, Ballen DF, Parra Medina R, Ria\u00f1o-Moreno JC. Neuroendocrine neoplasms as a lynch syndrome manifestation: a case report and comprehensive literature review. Front Endocrinol (Lausanne). 2025, 16:1587889. 10.3389\/fendo.2025.1587889","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-16-0693","article-title":"Prevalence and penetrance of major genes and polygenes for colorectal cancer","volume":"26","author":"Win AK","year":"2017","unstructured":"Win AK, Jenkins MA, Dowty JG, et al.. Prevalence and penetrance of major genes and polygenes for colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2017, 26:404-12. 10.1158\/1055-9965.EPI-16-0693","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.14309\/crj.0000000000001718","article-title":"Genetic predisposition and multifocal cancer: a complex case of Lynch syndrome","volume":"12","author":"Glover C","year":"2025","unstructured":"Glover C, Russell C, Rida A, et al.. Genetic predisposition and multifocal cancer: a complex case of Lynch syndrome. ACG Case Rep J. 2025, 12:e01718. 10.14309\/crj.0000000000001718","journal-title":"ACG Case Rep J"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-17-0735","article-title":"Landscape of tumor mutation load, mismatch repair deficiency, and PD-L1 expression in a large patient cohort of gastrointestinal cancers","volume":"16","author":"Salem ME","year":"2018","unstructured":"Salem ME, Puccini A, Grothey A, et al.. Landscape of tumor mutation load, mismatch repair deficiency, and PD-L1 expression in a large patient cohort of gastrointestinal cancers. Mol Cancer Res. 2018, 16:805-12. 10.1158\/1541-7786.MCR-17-0735","journal-title":"Mol Cancer Res"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2010-0560-OA","article-title":"Loss of expression of DNA mismatch repair proteins is rare in pancreatic and small intestinal neuroendocrine tumors","volume":"135","author":"Arnason T","year":"2011","unstructured":"Arnason T, Sapp HL, Rayson D, Barnes PJ, Drewniak M, Nassar BA, Huang WY. Loss of expression of DNA mismatch repair proteins is rare in pancreatic and small intestinal neuroendocrine tumors. Arch Pathol Lab Med. 2011, 135:1539-44. 10.5858\/arpa.2010-0560-OA","journal-title":"Arch Pathol Lab Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.12.6870","article-title":"Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma","volume":"95","author":"Herman JG","year":"1998","unstructured":"Herman JG, Umar A, Polyak K, et al.. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci. 1998, 95:6870-5. 10.1073\/pnas.95.12.6870","journal-title":"Proc Natl Acad Sci"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1023\/B:FAME.0000039861.30651.c8","article-title":"Promoter hypermethylation frequency and BRAF mutations distinguish hereditary non-polyposis colon cancer from sporadic MSI-H colon cancer","volume":"3","author":"McGivern A","year":"2004","unstructured":"McGivern A, Wynter CV, Whitehall VL, et al.. Promoter hypermethylation frequency and BRAF mutations distinguish hereditary non-polyposis colon cancer from sporadic MSI-H colon cancer. Fam Cancer. 2004, 3:101-7. 10.1023\/B:FAME.0000039861.30651.c8","journal-title":"Fam Cancer"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djh034","article-title":"Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability","volume":"96","author":"Umar A","year":"2004","unstructured":"Umar A, Boland CR, Terdiman JP, et al.. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 2004, 96:261-8. 10.1093\/jnci\/djh034","journal-title":"J Natl Cancer Inst"},{"key":"ref15","unstructured":"Network NCC. Neuroendocrine and adrenal tumors. (2026). Accessed. 01\/15\/2026: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/neuroendocrine.pdf."},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01013","article-title":"Randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors (ECOG-ACRIN E2211)","volume":"41","author":"Kunz PL","year":"2023","unstructured":"Kunz PL, Graham NT, Catalano PJ, et al.. Randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors (ECOG-ACRIN E2211). J Clin Oncol. 2023, 41:1359-69. 10.1200\/JCO.22.01013","journal-title":"J Clin Oncol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.202275","article-title":"Appropriate use criteria for somatostatin receptor PET imaging in neuroendocrine tumors","volume":"59","author":"Hope TA","year":"2018","unstructured":"Hope TA, Bergsland EK, Bozkurt MF, et al.. Appropriate use criteria for somatostatin receptor PET imaging in neuroendocrine tumors. J Nucl Med. 2018, 59:66-74. 10.2967\/jnumed.117.202275","journal-title":"J Nucl Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-012-2330-6","article-title":"The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours","volume":"40","author":"Bodei L","year":"2013","unstructured":"Bodei L, Mueller-Brand J, Baum RP, et al.. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2013, 40:800-16. 10.1007\/s00259-012-2330-6","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-4070","article-title":"FDA approval summary: Pembrolizumab for the treatment of microsatellite instability-high solid tumors","volume":"25","author":"Marcus L","year":"2019","unstructured":"Marcus L, Lemery SJ, Keegan P, Pazdur R. FDA approval summary: Pembrolizumab for the treatment of microsatellite instability-high solid tumors. Clin Cancer Res. 2019, 25:3753-8. 10.1158\/1078-0432.CCR-18-4070","journal-title":"Clin Cancer Res"},{"key":"ref20","unstructured":"KEYTRUDA (pembrolizumab) prescribing information. Merck & Co., Inc. MSI\u2011H\/dMMR solid tumor indication. (2026). Accessed. 01\/19\/2026: https:\/\/www.keytrudahcp.com\/efficacy\/msi-h-dmmr\/."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/483034-pancreatic-neuroendocrine-tumor-in-lynch-syndrome-expanding-the-tumor-spectrum-of-mismatch-repair-deficiency","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T14:13:53Z","timestamp":1780928033000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/483034-pancreatic-neuroendocrine-tumor-in-lynch-syndrome-expanding-the-tumor-spectrum-of-mismatch-repair-deficiency"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,8]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.110453","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,8]]}}}